BACKGROUND Several studies performed before the advent of thrombolysis have shown
that the presence of ventricular arrhythmias is an independent risk factor for subsequent …

Objectives: The objective of the study was to evaluate the effect of an angiotensin receptor
blocker on left ventricular (LV) structure and function when added to prescribed heart failure …

Objectives: The objective of this study was to test the hypothesis that the severity of left
ventricular remodeling predicts the response to treatment and outcomes in chronic heart …

Diabetes and oxidative stress concur to cardiac myocyte death in various experimental
settings. We assessed whether N-acetyl-l-cysteine (NAC), an antioxidant and glutathione …

The cytokine erythropoietin (EPO) protects the heart from ischemic injury, in part by
preventing apoptosis. However, EPO administration can also raise the hemoglobin …

Background Troponin changes over time have been suggested to allow for an early
diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin …

Abstract Type I mucopolysaccharidosis (MPS I) is a lysosomal storage disorder caused by
the deficiency of α-L-iduronidase, which results in glycosaminoglycan accumulation in …

Abstract Background: Whether cyclosporine A (CsA) has beneficial effects in reperfused
myocardial infarction (MI) is debated. Objectives: This study investigated whether CsA …

Background Patients with end-stage heart failure are often refractory to maximal oral
therapy, and they have high mortality rates, poor quality of life, and frequent hospitalizations …

PURPOSE: B-type natriuretic peptide is one of the most sensitive and specific biohumoral
markers of heart failure. We hypothesized that B-type natriuretic peptide changes during …